
CLAIMS

1. Use of a VAP-1 inhibitor in the manufacture of a medicament for the prevention and/or treatment of migraine.

2. The use according to claim 1, wherein the VAP-1 inhibitor is a compound of Formula (III) or a pharmaceutically acceptable salt, or N-oxide thereof



(III)

wherein

R^1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, a 3-7 membered cycloalkyl ring, $-OR^5$, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, and $-NR^6S(O)_2R^5$; wherein


R^{4A}, R^{4B} R^5 and R^6 are each independently selected from hydrogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl, or

R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3-7-membered cyclic amino group, optionally substituted by one or more substituents selected from: halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, $-CONH_2$, $-SO_2NH_2$, $-NH_2$, $-NHC_{1-4}$-alkyl, -NHhalo-C_{1-4}-alkyl;

R^3 is a 3-7 membered heterocyclic ring, a 3-7 membered cycloalkyl ring, or a 5 or 6-membered heteroaryl ring, any one of the rings being optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, $-OR^5$, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, $-SO_2R^5$, $-SO_2NR^{4A}R^{4B}$ and $-NR^6S(O)_2R^5$.

3. The use according to claim 2, wherein R^1 is a phenyl ring optionally substituted with one or more substituents as defined in claim 2.

4. The use according to claim 2 or 3, wherein the VAP-1 inhibitor is a compound of Formula (IIIa) or a pharmaceutically acceptable salt, or N-oxide thereof



(IIIa)

.

5. The use according to any of claims 2 to 4, wherein R^3 is a 3-7 membered heterocyclic ring optionally substituted with one or more substituents as defined in claim 2.


6. The use according to any one of claims 2 to 5, wherein R^3 is a piperazine or morpholine ring optionally substituted with one or more substituents as defined in claim 2.

7. The use according to claim 6, wherein piperazine or morpholine ring of R^3 is joined to the rest of the molecule through a nitrogen atom of that piperazine or morpholine ring.

8. The use according to any of claims 2 to 7, wherein R^3 is a piperazine ring substituted with at least one substituent as defined in claim 2 on a nitrogen atom in that piperazine ring.

9. The use according to any one of claims 2 to 7, wherein the VAP-1 inhibitor is selected from the group consisting of
1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazin-1-yl)ethan-1-one;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine; and
1-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-4-methanesulfonylpiperazine.

10. The use according to claim 1, wherein the VAP-1 inhibitor is a compound of Formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof



(I)

wherein:

Y is selected from hydrogen, hydroxyl, $-NH_2$, $-NH-C_{1-4}$-alkyl, $-NH$-halo-C_{1-4}-alkyl, or $-C_{1-4}$-alkoxy;

Z is selected from hydrogen, halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, -$CONH_2$, -SO_2NH_2, -NH_2, -NHC_{1-4}-alkyl, or -NHhalo-C_{1-4}-alkyl;

R^1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, a 3-7 membered cycloalkyl ring, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, and -$NR^6S(O)_2R^5$; wherein

R^{4A}, R^{4B} R^5 and R^6 are each independently selected from hydrogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl, or

R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from: halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, -$CONH_2$, -SO_2NH_2, -NH_2, -NHC_{1-4}-alkyl, -NHhalo-C_{1-4}-alkyl;

X is selected from –N= or –$C(R^2)$=;

R^2 is selected from hydrogen, halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$;


W is a phenyl ring or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, oxo C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{7A}R^{7B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{7A}R^{7B}$, -$C(O)NR^{7A}R^{7B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{7A}R^{7B}$ and -$NR^6S(O)_2R^5$;

R^{7A} and R^{7B} are independently hydrogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl.

V is selected from a bond, -O-, -$N(R^6)$-, -(C=O)-, -$CONR^6$-, -$NR^6C(O)$-, or -C_{1-4}-alkylene-, wherein the C_{1-4}-alkylene group is optionally substituted by halogen, and wherein any one of the carbon atoms of the C_{1-4}-alkylene group may be replaced by –O- or -$N(R^6)$-;

R^3 is selected from hydrogen, -C_{1-4}-alkyl, -C_{1-4}-alkyl-C_{1-4}-alkoxy or a 3-7 membered heterocyclic ring or 3-7 membered cycloalkyl ring, or a 5 or 6-membered heteroaryl ring, any one of the rings being optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$;

with the proviso that groups –W-V-R^3 and/or R^1 are not




wherein

n is 0, 1, or 2;

R' and R'' are independently selected from the group consisting of H, -C_1-C_6alkyl, –(C=O)-C_1-C_6 alkyl and –(C=O)OC$(CH_3)_3$; and

R''' is H, OH, or C_1-C_6 alkyl.

11. The use according to claim 1, wherein the VAP-1 inhibitor is a compound of Formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof



(I)

wherein:

Y is selected from hydrogen, hydroxyl, -NH_2, -NH-C_{1-4}-alkyl, -NH-halo-C_{1-4}-alkyl, or -C_{1-4}-alkoxy;

Z is selected from hydrogen, halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, -$CONH_2$, -SO_2NH_2, -NH_2, -NHC_{1-4}-alkyl, or -NHhalo-C_{1-4}-alkyl;

R^1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, and -$NR^6S(O)_2R^5$; wherein

R^{4A}, R^{4B} R^5 and R^6 are each independently selected from hydrogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl, or

R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3 to 7-membered cyclic amino group, optionally substituted by one or more substituents selected from: halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, -$CONH_2$, -SO_2NH_2, -NH_2, -NHC_{1-4}-alkyl, -NHhalo-C_{1-4}-alkyl;

X is selected from –N= or –C(R^2)=;

R^2 is selected from hydrogen, halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$;

W is a phenyl ring or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{7A}R^{7B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{7A}R^{7B}$, -$C(O)NR^{7A}R^{7B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{7A}R^{7B}$ and -$NR^6S(O)_2R^5$;

R^{7A} and R^{7B} are independently hydrogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl.

V is selected from a bond, -O-, -N(R^6)-, -(C=O)-, -CONR^6-, -NR^{6}C(O)-, or -C_{1-4}-alkylene-, wherein the C_{1-4}-alkylene group is optionally substituted by halogen, and wherein any one of the carbon atoms of the C_{1-4}-alkylene group may be replaced by –O- or -N(R^6)-;
R^3 is hydrogen or a 3-7 membered heterocyclic ring or 3-7 membered cycloalkyl ring selected from cyclopropyl, cyclopentyl or cyclohexyl, or a 5 or 6-membered heteroaryl ring, any one of the rings being optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$.

12. The use according to claim 10 or 11, wherein

(i) Y is hydrogen;

(ii) Z is hydrogen;

(iii) R^1 is phenyl or 6-membered heteroaryl, optionally substituted with one or more substituents selected from halogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl; preferably R^1 is phenyl or pyridyl, optionally substituted with one or more substituents selected from F, Cl or CH_3; and/or

(iv) X is –C(R^2)=, and R^2 is hydrogen, halogen, cyano, C_{1-4}-alkyl, or halo-C_{1-4}-alkyl; preferably R^2 is hydrogen.

13. The use according to any of claims 10 to 12, wherein W is

(a) a phenyl ring optionally substituted with one or more substituents as defined in claim 10 or claim 11;

(b) a 6-membered heteroaryl ring selected from pyridine, pyridazine, pyrazine, or pyrimidine optionally substituted with one or more substituents as defined in claim 10 or claim 11;

(c) a 5-membered heteroaryl ring selected from oxazole, thiazole or imidazole optionally substituted with one or more substituents as defined in claim 10 or claim 11; or

(d) an imidazolyl ring optionally substituted as in claim 10, and wherein the imidazolyl ring is connected to the pyrrolopyridine core via an imidazolyl ring carbon atom.


14. The use according to any of claims 10 to 13, wherein W is optionally substituted with one or more substituents selected from fluoro, chloro, cyano, CH_3 or CF_3.

15. The use according to any of claims 10 to 14, wherein

(A) V is $–CH_2-$, $–(CH_2)_2-$, or $-N(R^6)CH_2-$, or $-CH_2-N(R^6)-$, optionally wherein, when dependent on claim 10, R^3 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl optionally substituted as defined in claim 10;

(B) R^3 is formed from $–NR^{4A}R^{4B}$ wherein R^{4A} and R^{4B}, together with the nitrogen atom to which they are attached join together to form a 4 to 7-membered heterocyclic ring optionally substituted as defined in claim 10 or claim 11; or

(C) R^3 is selected from the group consisting of:



wherein R^8 is selected from hydrogen, CH_3, $-CONH_2$, $-NHCONH_2$, $-S(O)_2CH_3$, $-COCH_3$.

16. The use according to claim 10 or 11, wherein VAP-1 inhibitor is a compound selected from the group consisting of

3-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridine;

4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridine;

4-({5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}methyl)morpholine;

4-{6-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridazin-3-yl}morpholine;

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrazin-2-yl}morpholine;

4-({5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}carbonyl)morpholine;

5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-(oxan-4-yl)pyrazin-2-amine;

1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperidin-4-amine;

N-(Cyclopropylmethyl)-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;

N-Cyclopropyl-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;

5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-(oxan-4-yl)pyrimidin-2-amine;

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}piperazin-2-one;

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}piperazin-2-one;

5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-cyclopropylpyridine-2-carboxamide;
3-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-(oxan-4-yl)pyridazine;
N-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}methanesulfonamide;
1-{4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,3-thiazol-2-yl}piperazine;
1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,3-oxazol-2-yl}piperazine;
1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,3-thiazol-2-yl}piperazine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-(oxan-4-yl)pyrimidin-2-amine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine;
4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine;
(2R,6S)-4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,6-dimethylmorpholine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,2-dimethylmorpholine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-1,4-oxazepane;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl}morpholine;
4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl}morpholine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methoxypyridin-2-yl}morpholine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4,6-dimethylpyridin-2-yl}morpholine;
2-Cyclopropyl-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidine;
5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one;
5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one;
4-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,2-dihydropyridin-2-one;
5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,2-dihydropyridin-2-one;
(2R,6S)-2,6-Dimethyl-4-{5-[3-(5-methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
N-(3-Methoxypropyl)-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-[2-(propan-2-yloxy)ethyl]pyrimidin-2-amine;
5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-[2-(propan-2-yloxy)ethyl]pyrimidin-2-amine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-1-methylpiperazin-2-one;


4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
N-(2-Ethoxyethyl)-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
N-(2-Ethoxyethyl)-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-imidazole;
1-({3-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}methyl)-4-methylpiperazine;
1-({4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}methyl)-4-methylpiperazine;
4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
1-({4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}methyl)-1H-imidazole;
4-({4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}methyl)morpholine;
1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazine;
4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(6-Methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(4-Bromophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(6-Methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{2-[6-(Morpholin-4-yl)pyridin-3-yl]-3H-imidazo[4,5-c]pyridin-3-yl}phenol;
4-(5-{3-[4-(Trifluoromethyl)phenyl]-3H-imidazo[4,5-c]pyridin-2-yl}pyridin-2-yl)morpholine;
4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyrimidine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-2-methylmorpholine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N,N-dimethylpyridin-2-amine;
5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N,N-dimethylpyrimidin-2-amine;
4-{4-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(4-Chloro-3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(5-Chloropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;

4-{5-[3-(5-Fluoropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(5-Methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(5-Chloropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(5-Methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyrimidine;
5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N,N-dimethylpyrimidin-2-amine;
N-(1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperidin-4-yl)acetamide;
1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazin-1-yl)ethan-1-one;
1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-1,4-diazepan-1-yl)ethan-1-one bis(trifluoroacetic acid);
N-(1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperidin-4-yl)methanesulfonamide;
1-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-4-methanesulfonylpiperazine;
4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazine-1-carboxamide;
(1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperidin-4-yl)urea;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazine-1-carboxamide;
4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,3-oxazol-2-yl}piperazine-1-carboxamide;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-1,4-diazepane-1-carboxamide;
4-(5-{3-Phenyl-3H-imidazo[4,5-c]pyridin-2-yl}pyrimidin-2-yl)morpholine;
4-{5-[3-(4-Cyclopropylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{4-Methyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{3-Fluoro-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(morpholin-4-yl)-1,4-dihydropyridin-4-one;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methyl-N-(oxan-4-yl)pyridin-2-amine;

N-(Cyclopropylmethyl)-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-amine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methyl-2-(1H-pyrazol-1-yl)pyridine;
(2R,6S)-2,6-Dimethyl-4-{5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
(2R,6S)-2,6-Dimethyl-4-{5-[3-(5-methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-amine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-1-methylpiperazin-2-one;
4-{4-Methyl-5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methylpyridin-2-yl}morpholine;
4-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N,N-dimethylpyridin-2-amine;
5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-amine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N,N,4-trimethylpyridin-2-amine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(oxolan-3-yloxy)pyridine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(oxan-4-yloxy)pyridine;
4-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one;
1-Cyclopropyl-4-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,2-dihydropyridin-2-one;
4-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1-cyclopropyl-1,2-dihydropyridin-2-one;
N-(2-Methoxyethyl)-N-methyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
(2R,6S)-2,6-Dimethyl-4-{5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-(oxan-4-yl)pyrimidin-2-amine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine;
2-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine;
3-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidine;
2-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrazine;
1-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]phenyl}carbonyl)-4-methylpiperazine;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-2,4-dimethyl-1H-imidazole;
4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}piperazin-2-one;
4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine;

4-{5-[1-(4-Methylphenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-(5-{1-Phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl}pyrimidin-2-yl)morpholine;
4-{5-[1-(5-Methylpyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
4-{5-[1-(4-Bromophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1H-pyrazole;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1H-pyrazole;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1H-imidazole;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-N,N-dimethylpyrimidin-2-amine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-cyclopropyl-1,2-dihydropyridin-2-one;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-N-(oxan-4-yl)pyrimidin-2-amine;
4-({5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridin-2-yl}methyl)morpholine;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-4-methylpyridin-2-amine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1,2-dihydropyridin-2-one;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-ethyl-1,2-dihydropyridin-2-one;
6-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-2,3-dihydropyridazin-3-one;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridin-2-amine;
3-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-5-fluoropyridine;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-N-(cyclopropylmethyl)pyrimidin-2-amine;
3-Chloro-5-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine;
5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-2-(1H-pyrazol-1-yl)pyridine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-3-fluoropyridine;
3-Chloro-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine;
4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-3-methylpyridine; and
1-Cyclopropyl-4-{1-phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl}-1,2-dihydropyridin-2-one,
or a pharmaceutically acceptable salt, or N-oxide thereof.

17. The use according to claim 1, wherein the VAP-1 inhibitor is a compound of Formula (II) or a pharmaceutically acceptable salt, or N-oxide thereof



(II)

wherein:

Y is selected from hydrogen, hydroxyl, -NH_2, -NH-C_{1-4}-alkyl, -NH-halo-C_{1-4}-alkyl, or -C_{1-4}-alkoxy;

Z is selected from hydrogen, halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, -$CONH_2$, -SO_2NH_2, -NH_2, -NHC_{1-4}-alkyl, or -NHhalo-C_{1-4}-alkyl;

R^1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, $NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, and -$NR^6S(O)_2R^5$; wherein

R^{4A}, R^{4B} R^5 and R^6 are each independently selected from hydrogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl, or

R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from: halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, -$CONH_2$, -SO_2NH_2, -NH_2, -NHC_{1-4}-alkyl, -NHhalo-C_{1-4}-alkyl;

R^{7A} and R^{7B} are independently hydrogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl; and wherein

the group –WVR^3 is selected from any one of groups (i) - (iv):

(i) W is a [6,5], [5,6], or [6,6] heteroaryl ring system comprising a phenyl ring or a 6-membered heteroaryl ring fused to a 5 or 6-membered heteroaryl or heterocyclic ring, the fused ring system being optionally substituted on either or both rings with one or more groups selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$, and

V is a direct bond, and

R^3 is hydrogen;

(ii) W is a phenyl ring or a 5 or 6-membered heteroaryl ring, either ring optionally substituted with one or more groups selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$, and

V is -NR^6-, and

R^3 is a C_{1-6}-alkyl group substituted with one or more substituents selected from the group consisting of: halogen, hydroxyl, cyano, oxo, and $NR^{7A}R^{7B}$;

(iii) W is a 5 or 6-membered heterocyclic ring optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$,

V is a direct bond, and

R^3 is a phenyl ring or a 5 or 6-membered heteroaryl ring optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$;

(iv) W is a direct bond, V is a group selected from **-$(C=O)$-$(CH_2)_n$-, -$CONR^6$-$(CH_2)_n$-, **-$NR^6C(O)$-$(CH_2)_n$-, **-$NR^6C(O)O$-$(CH_2)_n$- wherein the bond marked ** is connected to the rest of the molecule, or -C_{1-4}-alkylene-, wherein any one of the the -(CH_2)- groups, including the C_{1-4}-alkylene group, group is optionally substituted by halogen, and wherein any one of the carbon atoms of the C_{1-4}-alkylene group may be replaced by –O- or -$N(R^6)$-, and

n is 0, 1, 2, 3, or 4


R^3 is selected from:

a C_{1-6}-alkyl group optionally substituted with one or more substituents selected from the group consisting of: halogen, hydroxyl, cyano, oxo, C_{1-4} alkoxy, C_{1-4}alkoxy and $NR^{7A}R^{7B}$; or


a 3-7 membered heterocyclic or cycloalkyl ring, a phenyl ring, or a 5 or 6-membered heteroaryl ring, any of which rings is optionally substituted with a group selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, -OR^5, -$NR^{4A}R^{4B}$, -$NR^6C(O)OR^5$, -$NR^6C(O)R^5$, -$NR^6C(O)NR^{4A}R^{4B}$, -$C(O)NR^{4A}R^{4B}$, -$C(O)R^5$, -$C(O)OR^5$, -SO_2R^5, -$SO_2NR^{4A}R^{4B}$ and -$NR^6S(O)_2R^5$.

18. The use according to claim 16, wherein

(i) –WVR^3 is as defined in group (i) wherein W is a [6,5] heteroaryl ring system formed by fusing together phenyl and pyrrolidinyl or imidazolyl and wherein either ring is optionally substituted as set out in claim 16, preferably wherein W has the formula A1 or A2:



(A1)




(A2)

wherein W is optionally substituted on either ring as set out in claim 16, and wherein W is directly connected to the rest of the molecule via a carbon atom on the phenyl ring;

(ii) $-WVR^3$ is as defined in group (ii), and R^3 is C_{1-6}-alkyl substituted with one or more groups selected from fluoro, chloro, hydroxyl and C_{1-4}alkyl;

(iii) $-WVR^3$ is as defined in group (ii), and R^3 is $-CH_2C(CH_3)_2OH$;

(iv) $-WVR^3$ is as defined in group (iii), and W is a ring selected from piperidine, morpholine, pyrrolidine, and piperazine, any of which is optionally substituted as set out in claim 16, preferably wherein $-WVR^3$ is



wherein the bond marked ** is directly connected to the rest of the molecule; or

(v) $-WVR^3$ is as defined in group (iv), wherein V is selected from any one of $-CONR^6-$, $-CONR^6-(CH_2)-$, $NR^6C(O)-$, $-NR^6C(O)-(CH_2)-$, $-NR^6C(O)O-$, $-NR^6C(O)O-(CH_2)-$, $-(CH_2)-$, $-(CH_2)_2-$, and $-(CH_2)_3-$, and/or wherein R^3 is a group selected from phenyl, imidazolyl, tetrahydropyranyl, piperidinyl, and piperazinyl, and one of which rings is optionally substituted according to claim 16.

19. The use according to claim 17 or 18, wherein

(A) Y is hydrogen;

(B) Z is hydrogen; and/or

(C) R^6 is hydrogen.

20. The use according to claim 17, wherein the VAP-1 inhibitor is selected from the group consisting of

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2,3-dihydro-1H-indol-2-one;

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-1,3-benzodiazole;

1-({5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}amino)-2-methylpropan-2-ol;

2-Methyl-1-({5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}amino)propan-2-ol;

4-{4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]piperidin-1-yl}pyridine; bis(formic acid);

6-{4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]piperidin-1-yl}-3,4-dihydropyrimidin-4-one;

3-{[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]methyl}pyridine;
1-{3-[3-(4-chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]propyl}-1H-imidazole;
3-(4-Fluorophenyl)-*N*-(oxan-4-ylmethyl)-3H-imidazo[4,5-c]pyridine-2-carboxamide
or a pharmaceutically acceptable salt, or N-oxide thereof.

21. The use according to claim 1, wherein the VAP-1 inhibitor is selected from the group consisting of
4-{5-[3-(5-Fluoropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine;
5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-(oxan-4-yl)pyrimidin-2-amine;
N,*N*-Diethyl-5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
N,*N*-Diethyl-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
N,*N*-Diethyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
N,*N*-Diethyl-5-[3-(5-methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine;
4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine;
4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine;
5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-(oxan-4-yl)pyridin-2-amine;
2-(4,4-Difluoropiperidin-1-yl)-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridine;
4-{5-[3-(5-Chloropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine;
4-{4-Methyl-5-[3-(5-methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine;
4-{5-[3-(5-Fluoropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-N-(oxan-4-yl)pyridin-2-amine;
4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}thiomorpholine*;*
N-Cyclopropyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-amine;
5-[3-(6-Methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyridine;
2-(4-Fluoropiperidin-1-yl)-5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridine;
5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-[2-(morpholin-4-yl)ethyl]pyridin-2-amine;
5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-[2-(morpholin-4-yl)ethyl]pyridin-2-amine;
N-Cyclopropyl-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-amine;
N-Cyclopropyl-5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-amine;
5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-(propan-2-yl)pyridin-2-amine
5-[3-(6-Methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyrimidine;

5-[3-(5-Methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyrimidine;
5-[3-(5-Fluoropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyrimidine;
4-{4-[3-(6-Methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}morpholine;
5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyrimidine;
4-{4-[3-(5-Methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}morpholine;
2-Methyl-5-{2-[4-(pyrrolidin-1-yl)phenyl]-3H-imidazo[4,5-c]pyridin-3-yl}pyridine;
5-{2-[2-Fluoro-4-(pyrrolidin-1-yl)phenyl]-3H-imidazo[4,5-c]pyridin-3-yl}-2-methylpyridine;
4-{3-Fluoro-4-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}morpholine;
5-{2-[3-Fluoro-4-(pyrrolidin-1-yl)phenyl]-3H-imidazo[4,5-c]pyridin-3-yl}-2-methylpyridine;
N-{4-[3-(6-Methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}oxan-4-amine;
5-Methyl-2-{2-[4-(pyrrolidin-1-yl)phenyl]-3H-imidazo[4,5-c]pyridin-3-yl}pyridine;
5-{2-[4-(4-Fluoropiperidin-1-yl)phenyl]-3H-imidazo[4,5-c]pyridin-3-yl}-2-methylpyridine;
2-Chloro-5-[3-(4-chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridine
2-Chloro-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridine
or a pharmaceutically acceptable salt, or N-oxide thereof.

22. The use according to claim 1, wherein the VAP-1 inhibitor is selected from the group consisting of (*S*)-carbidopa, benserazide, LJP1207, LJP1586, mofegiline, BTT1023, RTU-1096, PXS4728 and ASP8232 or a hydrate or pharmaceutically acceptable salt thereof.

23. The use according to claim 1, wherein the VAP-1 inhibitor is (*S*)-carbidopa.

24. The use according to claim 1, wherein the VAP-1 inhibitor has the structure of any one of the specific VAP-1 inhibitor compounds, polypeptides or proteins disclosed herein.

25. The use according to any preceding claim, wherein migraine is selected from the group consisting of headache, chronic migraine; episodic migraine; medication overuse headache disorder (MOU); migraine without aura; migraine with aura; migraine aura without headache; ocular migraine; vestibular migraine; basilar migraine; hemiplegic migraine; ophthalmoplegic migraine; and tension-type headache (TTH).

26. The use according to claim 25, wherein migraine is medication overuse headache disorder (MOU).

27. The use according to any preceding claim, wherein the use is for the prevention of migraine.

28. The use according to any of claims 1 to 27, wherein the use is for the treatment of migraine.